[트럼프 시대]“Looking forward to restoring trust in the FDA” with Kennedy Jr.
U.S. President-elect Donald Trump announced on the 22nd (local time) that he would nominate Johns Hopkins University surgeon Marty Makary to head the Food and Drug Administration (FDA).
In a statement posted on the social networking service TruthSocial on this day, President-elect Trump said, “The FDA has lost the trust of the American people and has lost its main goal as a regulatory agency,” and added, “It is necessary for Dr. Marty Macari, a health policy expert, to correct the direction of the FDA and refocus it.” “There is.”
Trump added, “Under the leadership of Robert F. Kennedy Jr., he will work to address the epidemic of chronic childhood diseases by appropriately evaluating the hazardous chemicals contaminating our nation’s food supply and the drugs and biological agents administered to America’s youth.” did it
President-elect Trump said, “I am confident that Dr. Maccari, with his dedication to providing high-quality, low-cost care, will restore the FDA to the gold standard for scientific research and cut through the agency’s red tape to ensure Americans receive the medical care they deserve.” .
Although Macari does not make claims contrary to medical common sense like Kennedy Jr., he has maintained his stance against overtreatment in American hospitals.
He has served as a public interest advisor at a conservative medical think tank and appears regularly on Fox News. In 2019, during the Trump administration, he served as an advisor to the signing of an executive order requiring transparent disclosure of medical costs to patients.
Macari emphasized natural immunity during the COVID-19 pandemic and opposed mandatory vaccination.
The FDA, an agency under the Department of Health and Human Services, is the world’s most influential drug regulatory agency with a budget of more than $7 billion.
It confirms the safety of new treatments, medical devices, and vaccines, approves their marketing, and establishes and maintains safety standards for food, tobacco, cosmetics, and radiation-emitting products. The FDA director must be confirmed by the Senate of the U.S. Congress.
(Washington = News 1)
-
- great
- 0dog
-
- I’m sad
- 0dog
- I’m angry
- 0dog
- I recommend it
- dog
Hot news now
What are Dr. Marty Makary’s key priorities as the new FDA Director nominee?
Interview Between Time.news Editor and Dr. Marty Makary, Nominee for Director of the FDA
Time.news Editor (E): Good day, Dr. Makary. Thank you for joining us today. You have recently been nominated as the Director of the FDA by President-elect Trump. What does this nomination mean for you personally and professionally?
Marty Makary (M): Thank you for having me. This nomination is a profound honor, and it represents a significant opportunity to restore public trust in the FDA. The agency has faced many challenges, and I believe we can refocus its mission to prioritize patient safety and the promotion of high-quality healthcare.
E: President-elect Trump has been vocal about the loss of trust in the FDA. In your opinion, what are the key issues that have contributed to this loss?
M: Trust has been eroded primarily due to perceived conflicts of interest, regulatory inefficiencies, and a lack of transparency. The public deserves an FDA that prioritizes their health over business interests. By enhancing transparency around medical costs and treatment practices, and ensuring rigorous, independent evaluations of products, we can begin to rebuild that trust.
E: You’ve emphasized the importance of evaluating ‘hazardous chemicals’ in our food supply and medications for youth. Can you elaborate on your approach to addressing these issues?
M: Absolutely. We need to conduct thorough, science-backed assessments of the materials that enter our food and pharmaceutical systems. I propose creating a dedicated task force that continuously monitors and evaluates these substances, ensuring they meet rigorous safety standards and do not pose undue risk to our children.
E: It has been noted that you hold a stance against overtreatment in hospitals. Can you tell us more about why you believe this is a critical issue?
M: Overtreatment can not only lead to unnecessary harm but also inflate healthcare costs, creating barriers to access. By promoting a culture of restraint and encouraging more conservative treatment options when appropriate, we can ensure patients receive care that is truly beneficial and cost-effective.
E: During the COVID-19 pandemic, you supported the idea of natural immunity and opposed mandatory vaccinations. How do you reconcile this with the FDA’s role in vaccine oversight?
M: My stance focuses on personal choice and informed consent. While I fully support rigorous vaccine safety evaluation by the FDA, individuals should have the freedom to make informed decisions regarding their health. I aim to foster an environment where science informs these choices, rather than mandates that can undermine public trust.
E: Given the substantial budget the FDA operates with, exceeding $7 billion, how will you ensure that funds are used efficiently and effectively?
M: Efficiency is paramount. I plan to implement a comprehensive audit of existing programs to identify waste and areas for improvement. Additionally, fostering partnerships across governmental and non-governmental organizations can help leverage resources effectively, ensuring that taxpayer dollars contribute to meaningful outcomes in public health.
E: As you move forward with your nomination process, what message do you want to convey to the American public about your leadership style and vision for the FDA?
M: I want the public to know that my leadership will prioritize transparency, scientific integrity, and accessibility. Under my stewardship, the FDA will strive to be a beacon of trust and a reliable resource for the health of all Americans, ensuring we deliver on our promise of safe and effective medical products.
E: Thank you, Dr. Makary, for sharing your insights with us today. We look forward to seeing how your leadership could shape the future of the FDA.
M: Thank you for having me. It’s crucial we work together for the health and wellbeing of our communities.